<DOC>
	<DOCNO>NCT00729508</DOCNO>
	<brief_summary>Cat allergy increasingly prevalent condition , affect 10-15 % patient allergic rhinoconjunctivitis and/or asthma . Cat-PAD novel , synthetic , allergen-derived peptide desensitise vaccine , currently develop treatment cat allergy . This study investigate efficacy 4 treatment regimen Cat-PAD cat allergic subject follow challenge cat allergen environmental exposure chamber ( EEC ) .</brief_summary>
	<brief_title>Effectiveness Cat-PAD Treat Cat Allergy Cat Allergic Subjects</brief_title>
	<detailed_description>This study design multicentre , randomise , double-blind , placebo-controlled study 4 treatment regimen 120 cat allergic subject . A total 24 subject randomise treatment group . Each subject undergo screen 4 week treatment . Baseline challenge consist exposure cat allergen 3 hour EEC 4 visit successive day week first administration Cat-PAD placebo . Treatment administer intradermal injection flexor surface alternate forearm . There 5 treatment regimen involve administration Cat-PAD placebo . Post-treatment challenge ( PTC ) consist exposure cat allergen 3 hour EEC 4 visit successive day 18 week first administration study medication .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Minimum 1year documented history rhinoconjunctivitis ( Nasal symptom : sneezing , itching , rhinorrhoea , blockage ; Ocular symptom : itching , redness , soreness , water ) exposure cat . [ Subjects may also control asthma ( GINA classification 1 ) ] . Positive skin prick test cat allergen wheal diameter least 3mm large produce negative control . Subjects must achieve minimum qualify symptom score least one Symptom Diary Card EEC exposure third fourth day Baseline Challenge . Minimum qualify symptom score define TRSS least 10 possible 24 TNSS least 6 possible 12 . Subjects asthma fall GINA classification 2 ( partly control ) 3 ( uncontrolled ) . A history anaphylaxis cat allergen . Subjects cat specific IgE &gt; 100 kU/L . Subjects FEV1 &lt; 80 % predict . Subjects acute phase skin response cat allergen mean wheal diameter &gt; 50mm . Subjects suffer seasonal allergic rhinoconjunctivitis , complete clinical study outside local pollen season significant allergy animal dander avoid study period . Subjects tolerate baseline challenge EEC . Allergen immunotherapy last 12 month history Cat Dander immunotherapy . Subjects administration adrenaline contraindicate ( e.g . subject acute chronic symptomatic coronary heart disease severe hypertension ) . Subjects treat betablockers . History immunopathological disease . Positive test Hepatitis B , Hepatitis C HIV screen . Have history severe drug allergy anaphylactic reaction food . A known allergy thioglycerol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Cat allergy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Cat-PAD</keyword>
	<keyword>Environmental Exposure Chamber</keyword>
</DOC>